Article
For nearly half of U.S. urologists, malpractice insurance premiums in 2011 stayed the same as 2010 levels, according to a recent survey.
Study results show CVAC 2.0 is safe, efficacious for wide range of kidney stones
FDA Advisory Committee unanimously votes against talazoparib plus enzalutamide for mCRPC
FDA Advisory Committee finds evidence for UGN-102 inconclusive, cites uncertainty in benefit-risk
Pivotal trial launches of 64Cu-SAR-bisPSMA in BCR of prostate cancer
2 Commerce Drive
Cranbury, NJ 08512